NCT03348904 - Nivolumab and Epacadostat With Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 27, 2017

Primary Completion Date

May 22, 2018

Study Completion Date

May 22, 2018

Conditions

Lung Cancer

Interventions

DRUG

Nivolumab

Nivolumab administered intravenously at the protocol-defined dose every 3 weeks.

DRUG

Epacadostat

Epacadostat administered orally at the protocol-defined dose twice daily.

DRUG

Placebo

Matching placebo for epacadostat administered orally twice daily.

DRUG

Carboplatin

Carboplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

DRUG

Cisplatin

Cisplatin administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

DRUG

Gemcitabine

Gemcitabine administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

DRUG

Paclitaxel

Paclitaxel administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles.

DRUG

Pemetrexed

Pemetrexed administered intravenously at the protocol-defined dose every 3 weeks for up to 4 cycles. Optional continuation maintenance every 3 weeks, if eligible.

Trial Locations (2)

67214

Cancer Center of Kansas, Wichita

92801

Pacific Cancer Medical Center, Inc, Anaheim